NEW YORK (GenomeWeb) – Invivoscribe Technologies today announced that it has signed an agreement with Astellas Pharma to develop a companion diagnostic for an investigational drug.

Under the terms of the agreement, Invivoscribe will develop and commercialize a companion diagnostic based on the FLT3 tyrosine kinase gene and use the international harmonized signal ration test to stratify and enroll acute myeloid leukemia (AML) patients for Astellas clinical trials of the drug candidate ASP2215 in the US, Europe, Japan, and other countries.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers are refining a tool to predict a woman's risk of developing breast cancer, according to the Guardian.

According to Stat News, the partial government shutdown in the US could soon affect the ability of the Food and Drug Administration to review new drugs.

In PNAS this week: gypsy moth genome sequenced, phylogenomic analysis of Polyneopterans, and more.

CNN reports that people's genes tend to have a greater influence on their risk of developing disease than their environment, but it varies by phenotype.